We are thankful for the valuable comments of Dr Ito on our article (1). First of all, the age of the patients in the groups are homogeneous, not statistically different. We found high procalcitonin levels only in patients with prostate cancer, C-reactive protein was not different between the groups. This point was shown in Table-1.
It is well known that chronic diseases are associated with elevated C-reactive protein levels and not with procalcitonin levels. Finally, I agree with Dr. Ito that the level of procalcitonin levels in cancer group must be evaluated, but in our series the proportion of radical treatment is very low; so only comparision of the Gleason scores will not be objective. Further studies including high number of patients are needed to define the relationship between inflammatory markers and prostate cancer.
Best regards
REFERENCE
Ilktac A, Kalkan S, Caliskan S. C-reactive protein and procalcitonin levels in prostate cancer. Int J Clin Pract. 2021;75:e13935.